ATLANTA, March 19, 2025 – Femasys, Inc. (Nasdaq: FEMY), a leading innovator in women’s health, has announced a strategic partnership with CNY Fertility, a nationwide network of fertility centers, to offer its FemaSeed intratubal insemination treatment across CNY’s 11 locations.
This collaboration aims to broaden patient access to FemaSeed, an advanced fertility treatment designed as a first-line option for individuals facing infertility challenges. By integrating FemaSeed into its services, CNY Fertility continues its mission to provide high-quality, affordable reproductive care.
“We are excited to partner with CNY Fertility, a respected leader in infertility care, to further expand access to FemaSeed for patients seeking innovative fertility solutions,” said Kathy Lee-Sepsick, CEO of Femasys. “This partnership underscores our commitment to improving reproductive health by delivering accessible and effective in-office treatments.”
Dr. Robert Kiltz, Founder and Director of CNY Fertility, emphasized the significance of the collaboration, stating, “At CNY Fertility, our goal is to provide comprehensive and affordable fertility solutions. FemaSeed represents an exciting advancement in reproductive medicine, offering our patients another option as they pursue their journey to parenthood.”
With this partnership, Femasys and CNY Fertility aim to enhance fertility care by making cutting-edge treatment more widely available, providing new hope for individuals and couples seeking to expand their families.
Related topics:
Australia to Slash Costs for Contraception, Endometriosis, and IVF Medications
19% of Men Experience Erectile Dysfunction After COVID-19, With 9% Still Affected at 2 Years
